|
| 36928279 | Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 37542936 | Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis. | Eur J Cancer | 2023 |
| 36980708 | CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data. | Cancers (Basel) | 2023 |
| 37030280 | Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial. | Gynecol Oncol | 2023 |
| 36672287 | British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer. | Cancers (Basel) | 2023 |
| 36482193 | Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10. | Br J Cancer | 2023 |
| 34865316 | Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER-2 cohort study. | BJOG | 2022 |
| 35351333 | Modifiable pre-treatment factors are associated with quality of life in women with gynaecological cancers at diagnosis and one year later: Results from the HORIZONS UK national cohort study. | Gynecol Oncol | 2022 |
| 35454861 | CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis. | Cancers (Basel) | 2022 |
| 35690073 | Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. | Lancet Oncol | 2022 |
| 35870374 | Letter comments on: Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers. | ESMO Open | 2022 |
| 36139523 | Investigating the Impact of Ultra-Radical Surgery on Survival in Advanced Ovarian Cancer Using Population-Based Data in a Multicentre UK Study. | Cancers (Basel) | 2022 |
| 36066851 | EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study). | Future Oncol | 2022 |
| 33357510 | Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. | Lancet Oncol | 2021 |
| 33740262 | Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. | Cancer | 2021 |
| 33612336 | Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee. | Gynecol Oncol | 2021 |
| 33551198 | Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" Gynecol. Oncol. 154 (2019) 441-448. | Gynecol Oncol | 2021 |
| 34016703 | Metronomic oral cyclophosphamide in relapsed ovarian cancer. | Int J Gynecol Cancer | 2021 |
| 34059348 | OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer. | Gynecol Oncol | 2021 |
| 34085677 | Microfluidic technologies for immunotherapy studies on solid tumours. | Lab Chip | 2021 |
| 34162658 | Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer. | Cancer Epidemiol Biomarkers Prev | 2021 |
| 32321768 | Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors. | Int J Gynecol Cancer | 2020 |
| 32087992 | Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" [Gynecol. Oncol. 154 (2019) 441-448]. | Gynecol Oncol | 2020 |
| 32059825 | European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. | Maturitas | 2020 |
| 32046979 | European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. | Int J Gynecol Cancer | 2020 |
| 31922558 | Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis. | JAMA Netw Open | 2020 |
| 33077258 | A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer. | Gynecol Oncol | 2020 |
| 32554541 | Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). | Clin Cancer Res | 2020 |
| 32473302 | Prognostic gene expression signature for high-grade serous ovarian cancer. | Ann Oncol | 2020 |
| 32305099 | Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. | Lancet Oncol | 2020 |
| 32404377 | European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and industry partners - a new Model D for drug and medical device development. | Int J Gynecol Cancer | 2020 |
| 31791688 | Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. | Lancet | 2019 |
| 29460478 | Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience. | BJOG | 2018 |
| 30134598 | rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. | Int J Mol Sci | 2018 |
| 30104763 | Copy number signatures and mutational processes in ovarian carcinoma. | Nat Genet | 2018 |
| 29979793 | Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. | PLoS One | 2018 |
| 30348046 | Managing vulvovaginal atrophy after breast cancer. | Post Reprod Health | 2018 |
| 29555990 | Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. | Br J Cancer | 2018 |
| 27993794 | Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours. | Ann Oncol | 2017 |
| 28359078 | Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium. | Br J Cancer | 2017 |
| 28103614 | Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. | Br J Cancer | 2017 |
| 28346442 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. | Nat Genet | 2017 |
| 29029385 | Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. | Oncotarget | 2017 |
| 28954785 | The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma. | Clin Cancer Res | 2017 |
| 27677730 | No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. | Cancer Epidemiol Biomarkers Prev | 2017 |
| 25940428 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. | Gynecol Oncol | 2016 |
| 27601076 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. | Nat Commun | 2016 |
| 27595995 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. | J Med Genet | 2016 |
| 27533245 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. | Oncotarget | 2016 |
| 27228289 | Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. | Br J Cancer | 2016 |